1396P Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM cohort: The ELY study
- Resource Type
- Source
- Annals of Oncology. 31:S885-S886
- Subject
business.industry Immune checkpoint inhibitors Hematology medicine.disease Oncology Cohort Cancer research Medicine Biomarker (medicine) Non small cell Progression-free survival business Lung cancer Anti pd1 - Language
- ISSN
- 0923-7534